Accepted Manuscript Colorectal histology is associated with an increased risk of local failure in lung metastases treated with stereotactic ablative radiotherapy (SABR) Michael S. Binkley, BA, Nicholas Trakul, MD PhD, Lisa Rose Jacobs, BA, Rie von Eyben, MS, Quynh-Thu Le, MD, Peter G. Maxim, PhD, Billy W. Loo, Jr., MD PhD, David Benjamin Shultz, MD PhD, Maximilian Diehn, MD PhD PII:
S0360-3016(15)00377-6
DOI:
10.1016/j.ijrobp.2015.04.004
Reference:
ROB 22854
To appear in:
International Journal of Radiation Oncology • Biology • Physics
Received Date: 14 December 2014 Revised Date:
30 March 2015
Accepted Date: 2 April 2015
Please cite this article as: Binkley MS, Trakul N, Jacobs LR, von Eyben R, Le Q-T, Maxim PG, Loo Jr. BW, Shultz DB, Diehn M, Colorectal histology is associated with an increased risk of local failure in lung metastases treated with stereotactic ablative radiotherapy (SABR), International Journal of Radiation Oncology • Biology • Physics (2015), doi: 10.1016/j.ijrobp.2015.04.004. This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
ACCEPTED MANUSCRIPT
Colorectal histology is associated with an increased risk of local failure in lung metastases treated with stereotactic ablative radiotherapy (SABR)
RI PT
Michael S. Binkley BA1, Nicholas Trakul MD PhD3, Lisa Rose Jacobs BA1, Rie von Eyben MS, Quynh-Thu Le MD1, Peter G. Maxim PhD1, Billy W. Loo Jr. MD PhD1, David Benjamin Shultz, MD PhD1#, Maximilian Diehn MD PhD1,2#
#
M AN U
CO-CORRESPONDING AUTHORS
SC
1. Department of Radiation Oncology and Cancer Institute, Stanford University School of Medicine 2. Institute for Stem Cell Biology & Regenerative Medicine, Stanford University School of Medicine 3. Department of Radiation Oncology, University of Southern California Keck School of Medicine, Los Angeles, California
Maximilian Diehn M.D. Ph.D. Department of Radiation Oncology Institute for Stem Cell Biology & Regenerative Medicine and Cancer Institute Stanford University School of Medicine E-mail: [email protected] Phone: (650) 721-1550 Fax: (650) 725-8231
TE D
AND
EP
David Benjamin Shultz M.D. Ph.D. Department of Radiation Oncology and Cancer Institute Stanford University School of Medicine 875 Blake Wilbur Drive Stanford, CA 94305 E-mail: [email protected]
AC C
Running Head
SABR for lung metastases Disclosures of potential conflicts of interest BWL has received speaking honoraria from Varian Medical Systems. MD, BWL, PGM, and QL receive research support from Varian Medical Systems. Keywords Stereotactic Ablative Radiotherapy, lung metastases
ACCEPTED MANUSCRIPT
Blinded Manuscript TITLE: Colorectal histology is associated with an increased risk of local failure
RI PT
in lung metastases treated with stereotactic ablative radiotherapy (SABR) Abstract
Purpose: Stereotactic Ablative Radiotherapy (SABR) is increasingly used to treat
SC
lung oligometastases. We set out to determine the safety and efficacy of this
M AN U
approach and to identify factors associated with outcomes.
Methods and Materials: We conducted a retrospective study of patients treated with SABR for metastatic lung tumors at our institution from 2003-2014. We assessed the association between various patient and treatment factors with local failure (LF), progression, subsequent treatment, systemic treatment, and overall survival (OS)
TE D
using univariate and multivariate analyses. Results: We identified 122 tumors in 77 patients meeting inclusion criteria for this
EP
study. Median follow up was 22 months. The 12- and 24-month cumulative incidence of LF were 8.7% and 16.2%, respectively; the 24-month cumulative incidences of
AC C
progression, subsequent treatment, and subsequent systemic treatment were 75.2%, 64.5%, and 35.1%, respectively. 24-month OS was 74.6% and median OS was 36 months. Colorectal metastases had a significantly higher cumulative incidence of LF at 12 and 24 months (25.5% and 42.2%), compared to all other histologies (4.4% and 9.9%; p
S0360-3016(15)00377-6
DOI:
10.1016/j.ijrobp.2015.04.004
Reference:
ROB 22854
To appear in:
International Journal of Radiation Oncology • Biology • Physics
Received Date: 14 December 2014 Revised Date:
30 March 2015
Accepted Date: 2 April 2015
Please cite this article as: Binkley MS, Trakul N, Jacobs LR, von Eyben R, Le Q-T, Maxim PG, Loo Jr. BW, Shultz DB, Diehn M, Colorectal histology is associated with an increased risk of local failure in lung metastases treated with stereotactic ablative radiotherapy (SABR), International Journal of Radiation Oncology • Biology • Physics (2015), doi: 10.1016/j.ijrobp.2015.04.004. This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
ACCEPTED MANUSCRIPT
Colorectal histology is associated with an increased risk of local failure in lung metastases treated with stereotactic ablative radiotherapy (SABR)
RI PT
Michael S. Binkley BA1, Nicholas Trakul MD PhD3, Lisa Rose Jacobs BA1, Rie von Eyben MS, Quynh-Thu Le MD1, Peter G. Maxim PhD1, Billy W. Loo Jr. MD PhD1, David Benjamin Shultz, MD PhD1#, Maximilian Diehn MD PhD1,2#
#
M AN U
CO-CORRESPONDING AUTHORS
SC
1. Department of Radiation Oncology and Cancer Institute, Stanford University School of Medicine 2. Institute for Stem Cell Biology & Regenerative Medicine, Stanford University School of Medicine 3. Department of Radiation Oncology, University of Southern California Keck School of Medicine, Los Angeles, California
Maximilian Diehn M.D. Ph.D. Department of Radiation Oncology Institute for Stem Cell Biology & Regenerative Medicine and Cancer Institute Stanford University School of Medicine E-mail: [email protected] Phone: (650) 721-1550 Fax: (650) 725-8231
TE D
AND
EP
David Benjamin Shultz M.D. Ph.D. Department of Radiation Oncology and Cancer Institute Stanford University School of Medicine 875 Blake Wilbur Drive Stanford, CA 94305 E-mail: [email protected]
AC C
Running Head
SABR for lung metastases Disclosures of potential conflicts of interest BWL has received speaking honoraria from Varian Medical Systems. MD, BWL, PGM, and QL receive research support from Varian Medical Systems. Keywords Stereotactic Ablative Radiotherapy, lung metastases
ACCEPTED MANUSCRIPT
Blinded Manuscript TITLE: Colorectal histology is associated with an increased risk of local failure
RI PT
in lung metastases treated with stereotactic ablative radiotherapy (SABR) Abstract
Purpose: Stereotactic Ablative Radiotherapy (SABR) is increasingly used to treat
SC
lung oligometastases. We set out to determine the safety and efficacy of this
M AN U
approach and to identify factors associated with outcomes.
Methods and Materials: We conducted a retrospective study of patients treated with SABR for metastatic lung tumors at our institution from 2003-2014. We assessed the association between various patient and treatment factors with local failure (LF), progression, subsequent treatment, systemic treatment, and overall survival (OS)
TE D
using univariate and multivariate analyses. Results: We identified 122 tumors in 77 patients meeting inclusion criteria for this
EP
study. Median follow up was 22 months. The 12- and 24-month cumulative incidence of LF were 8.7% and 16.2%, respectively; the 24-month cumulative incidences of
AC C
progression, subsequent treatment, and subsequent systemic treatment were 75.2%, 64.5%, and 35.1%, respectively. 24-month OS was 74.6% and median OS was 36 months. Colorectal metastases had a significantly higher cumulative incidence of LF at 12 and 24 months (25.5% and 42.2%), compared to all other histologies (4.4% and 9.9%; p
